Predictive Value of Sirtuins in Acute Myocardial Infarction - Bridging the Bench to the Clinical Practice

Author(s): Arquimedes G. Junior*, Thiago L. de Almeida, Sara E.L. Tolouei, Andreia F. dos Santos, Francislaine A. dos Reis Lívero

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 2 , 2021

Become EABM
Become Reviewer


Acute myocardial infarction (AMI) is a non-transmissible condition with high prevalence, morbidity, and mortality. Different strategies for the management of AMI are employed worldwide, but its early diagnosis remains a major challenge. Many molecules have been proposed in recent years as predictive agents in the early detection of AMI, including troponin (C, T, and I), creatine kinase MB isoenzyme, myoglobin, heart-type fatty acid-binding protein, and a family of histone deacetylases with enzymatic activities named sirtuins. Sirtuins may be used as predictive or complementary treatment strategies and the results of recent preclinical studies are promising. However, human clinical trials and data are scarce, and many issues have been raised regarding the predictive values of sirtuins. The present review summarizes research on the predictive value of sirtuins in AMI. We also briefly summarize relevant clinical trials and discuss future perspectives and possible clinical applications.

Keywords: Cardiovascular diseases, heart attack, histone deacetylases, myocardial injury, ischemia, thrombolysis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 04 February, 2021
Page: [206 - 216]
Pages: 11
DOI: 10.2174/1381612826666201005153848
Price: $65

Article Metrics

PDF: 16